Monografie
Targeting cyclin dependent kinase 5 in hepatocellular carcinoma : a novel therapeutic approach
- Sprache
-
Englisch
- Anmerkungen
-
München, Ludwig-Maximilians-Universität, Diss., 2014
- Identifier
-
1055913947
Thema
Krebs; Onkologie; Hochschulschrift
Beteiligte Personen und Organisationen
- URN
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
26.01.2023, 13:58 MEZ
Objekttyp
- Monografie
Beteiligte
Ähnliche Objekte (12)
Targeting cyclin dependent kinase 5 in hepatocellular carcinoma : a novel therapeutic approach
Targeting the actin cytoskeleton with natural compounds : elucidating the underlying mechanism of apoptosis induction
Preclinical characterization of the myxobacterial compound pretubulysin as novel vascular disrupting agent
Loss of mitochondrial thioredoxin reductase delays angiogenic switch and impairs tumour growth
Role of the transcriptional coactivators Megakaryoblastic Leukemia Proteins 1 and 2 in tumorigenesis
The V-ATPase inhibitor archazolid : Impact on anoikis resistance in metastatic cancer cells
Cyclin-dependent kinase 5 stabilizes the hypoxia-inducible factor in hepatocellular carcinoma : a novel signaling mechanism with potential therapeutic relevance
Untersuchungen zur zellulären Seneszenz Cathepsin X-defizienter Zellen
Targeting V-ATPase influences cancer cell cholesterol metabolism and biophysical properties - a new option for HCC therapy
Targeting the endolysosomal system of cancer cells by inhibition of V-ATPase and TPC function
Novel treatment strategies and mechanisms of actin binding compounds in cancer therapy
The myxobacterial acetyl-CoA carboxylase inhibitor Soraphen A as a novel anti-metastatic and anti-proliferative agent
Targeting cyclin dependent kinase 5 in hepatocellular carcinoma : a novel therapeutic approach
Targeting the actin cytoskeleton with natural compounds : elucidating the underlying mechanism of apoptosis induction
Preclinical characterization of the myxobacterial compound pretubulysin as novel vascular disrupting agent
Loss of mitochondrial thioredoxin reductase delays angiogenic switch and impairs tumour growth
Role of the transcriptional coactivators Megakaryoblastic Leukemia Proteins 1 and 2 in tumorigenesis
The V-ATPase inhibitor archazolid : Impact on anoikis resistance in metastatic cancer cells
Cyclin-dependent kinase 5 stabilizes the hypoxia-inducible factor in hepatocellular carcinoma : a novel signaling mechanism with potential therapeutic relevance
Untersuchungen zur zellulären Seneszenz Cathepsin X-defizienter Zellen
Targeting V-ATPase influences cancer cell cholesterol metabolism and biophysical properties - a new option for HCC therapy
Targeting the endolysosomal system of cancer cells by inhibition of V-ATPase and TPC function
Novel treatment strategies and mechanisms of actin binding compounds in cancer therapy
The myxobacterial acetyl-CoA carboxylase inhibitor Soraphen A as a novel anti-metastatic and anti-proliferative agent
Targeting cyclin dependent kinase 5 in hepatocellular carcinoma : a novel therapeutic approach
Targeting the actin cytoskeleton with natural compounds : elucidating the underlying mechanism of apoptosis induction
Preclinical characterization of the myxobacterial compound pretubulysin as novel vascular disrupting agent
Loss of mitochondrial thioredoxin reductase delays angiogenic switch and impairs tumour growth
Role of the transcriptional coactivators Megakaryoblastic Leukemia Proteins 1 and 2 in tumorigenesis
The V-ATPase inhibitor archazolid : Impact on anoikis resistance in metastatic cancer cells
Cyclin-dependent kinase 5 stabilizes the hypoxia-inducible factor in hepatocellular carcinoma : a novel signaling mechanism with potential therapeutic relevance
Untersuchungen zur zellulären Seneszenz Cathepsin X-defizienter Zellen
Targeting V-ATPase influences cancer cell cholesterol metabolism and biophysical properties - a new option for HCC therapy
Targeting the endolysosomal system of cancer cells by inhibition of V-ATPase and TPC function
Novel treatment strategies and mechanisms of actin binding compounds in cancer therapy